
Tourmaline Bio, Inc.
Tourmaline Bio, Inc.(TRML)股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
trml · 股价预测 · 10 位分析师(近3月)· FMP · 更新于 2026年2月3日
分析师评级与共识
基于过去 3 个月内 10 位华尔街分析师
Hold
10 位分析师
共识
评级分布
12 个月目标价
High
$50.00
Consensus
$48.50
+1.1% upside
Low
$47.50
Median: $48 · Last Close: $47.98
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$48.50
1.1% upside
High Target
$50
4.2%
Low Target
$47.5
-1.0%
Current Price
$47.98
as of today
Based on analyst price targets, the TRML stock price prediction for the next 12 months ranges from $47.5 to $50. The consensus TRML price forecast of $48.50 implies 1.1% upside from the current price of $47.98.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $47.88 | ↓ 0.20% |
1-day model range: $47.87–$47.9. Peak: $47.9 (-0.20%).
长期股价预测
基于技术分析的股价预测
14 项技术面信号(SMA×6 + EMA×6 + RSI + MACD)· EEAT 方法论透明
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · TRML · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-09-15 | BMO Capital | Downgrade ↓ | Outperform→Market Perform |
| 2025-09-11 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2025-09-10 | Truist Securities | Downgrade ↓ | Buy→Hold |
| 2025-09-10 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-09-10 | Chardan Capital | Downgrade ↓ | Buy→Neutral |
| 2025-09-10 | Guggenheim | Downgrade ↓ | Buy→Neutral |
| 2025-09-09 | LifeSci Capital | Downgrade ↓ | Outperform→Market Perform |
| 2025-09-09 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2025-09-09 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2025-08-14 | Chardan Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Tourmaline Bio, Inc. (TRML) stock. Of the recent 24 rating actions, 0 were upgrades and 9 were downgrades. 10 analysts currently cover TRML.
分析师推荐趋势
TRML analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
财务预测:EPS 与营收一致预期
Revenue This Year
$9M
↓ 48.6% YoY
Revenue Next Year
$9M
↑ 0.0% YoY
EPS This Year
$-3.70
EPS Next Year
$-4.04
↑ 9.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast TRML EPS of $-3.70 for the current fiscal year, based on estimates from 7 analysts. The TRML revenue forecast is $9M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
TRML 股价预测由两类独立数据源支撑:来自 10 位华尔街分析师(S&P Global / FMP)的共识评级,以及基于历史日终价计算的技术分析。TRML 的共识目标价为 $48.50(+1.1% 上行空间),分析师共识为 Hold。
TRML 的短期预测(明日)为 $47.88(-0.20%)。
Tourmaline Bio, Inc. 在 NASDAQ 上市,代码 TRML。TRML 在 2027 年的整体展望偏中性/分化,在覆盖分析师中约 10% 对应 Hold 共识。
常见问题
TRML 预测 · 8 个问题根据 10 位华尔街分析师,TRML 的 12 个月平均目标价为 $48.50,最高 $50.00、最低 $47.50。若有图表,中位目标价可在上方查看。相对当前价 $47.98,隐含约 +1.1% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.